A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high - dose interferon for <font color="blue">melanoma_4</font> <font color="blue">._4</font> 
<br>
<br> PURPOSE <font color="blue">Nearly_3</font> <font color="blue">2000_5</font> <font color="blue">patients_5</font> <font color="blue">with_5</font> <font color="blue">stage_5</font> <font color="blue">IIB_5</font> <font color="blue">and_5</font> <font color="blue">III_5</font> <font color="blue">melanoma_5</font> <font color="blue">have_1</font> <font color="blue">participated_1</font> <font color="blue">in_1</font> <font color="blue">four_1</font> <font color="blue">multicenter_1</font> <font color="blue">,_1</font> <font color="blue">randomized_1</font> <font color="blue">trials_1</font> <font color="blue">,_1</font> <font color="blue">conducted_1</font> <font color="blue">by_1</font> <font color="blue">the_1</font> <font color="blue">Eastern_1</font> <font color="blue">Cooperative_1</font> <font color="blue">Oncology_1</font> <font color="blue">Group_1</font> <font color="blue">and_1</font> <font color="blue">the_1</font> <font color="blue">Intergroup_1</font> <font color="blue">,_1</font> investigating adjuvant high - dose IFN - alpha 2b therapy . The objectives of this study were to update the analyses of each individual trial and to analyze prognostic factors and <font color="blue">treatment_1</font> <font color="blue">effects_1</font> <font color="blue">based_1</font> <font color="blue">on_1</font> <font color="blue">pooled_1</font> <font color="blue">data_1</font> <font color="blue">._1</font> 
<br> EXPERIMENTAL DESIGN Survival and disease status were updated to April 2001 . Analysis of prognostic factors using optimized statistical models was based on data from <font color="blue">patients_1</font> <font color="blue">in_1</font> <font color="blue">E1684_1</font> <font color="blue">,_1</font> <font color="blue">E1690_1</font> <font color="blue">,_1</font> <font color="blue">E1694_1</font> <font color="blue">,_1</font> <font color="blue">and_1</font> <font color="blue">E2696_1</font> <font color="blue">._1</font> Analysis of treatment effects versus observation ( Obs ) was based on data from <font color="blue">713_3</font> <font color="blue">patients_3</font> <font color="blue">randomized_1</font> to high - dose IFN - alpha 2b ( HDI ) or Obs in Trials E1684 and E1690 . 
<br> RESULTS Updated analysis of E1684 , E1690 , and E1694 confirmed their original conclusions , now at median follow - up intervals of 2.1 - 12.6 years . Based on two - sided univariate log - rank analysis of pooled data from E1684 and E1690 ( median follow - up , 7.2 years ) , relapse - free survival ( RFS)-but not overall survival ( OS)-was significantly prolonged ( two - sided log - rank P value = 0.006 ) for patients treated with HDI versus Obs . Among all <font color="blue">patients_1</font> <font color="blue">,_1</font> prognostic factors that significantly negatively impacted RFS and OS included <font color="blue">ulceration_1</font> <font color="blue">,_1</font> <font color="blue">recurrent_1</font> <font color="blue">disease_1</font> <font color="blue">at_1</font> <font color="blue">entry_1</font> <font color="blue">,_1</font> <font color="blue">enrollment_1</font> <font color="blue">in_1</font> <font color="blue">E1684_1</font> <font color="blue">,_1</font> <font color="blue">and_1</font> <font color="blue">age_1</font> <font color="blue">>_1</font> <font color="blue">49_1</font> <font color="blue">years_1</font> <font color="blue">._1</font> Multivariate statistical models adjusting for these factors confirmed the statistically significant RFS benefit of HDI versus Obs but did not demonstrate a significant OS benefit in the pooled populations . 
<br> CONCLUSIONS In <font color="blue">patients_2</font> <font color="blue">with_1</font> <font color="blue">high_1</font> <font color="blue">-_1</font> <font color="blue">risk_1</font> <font color="blue">resected_1</font> <font color="blue">melanoma_1</font> <font color="blue">,_1</font> HDI is effective adjuvant therapy with strong evidence for improved RFS and evidence for moderate improvement in OS based on two prospective randomized studies but not the pooled analysis . Analyses of predictors of relapse and response are now needed to improve the therapeutic value of this modality .